Analysts fault FDA for market delay of Lilly’s prasugrel:
Eli Lilly and Co.’s frustrating attempt to get a ruling from federal regulators on its experimental blood thinner prasugrel may be a test case of life under a more cautious-and understaffed-U.S. Food and Drug Administration. That’s the opinion taken by many pharmaceutical analysts after the FDA missed its self-imposed Sept. 26 deadline to make a ruling on prasugrel. The FDA already had delayed its decision by three months after it agreed to give prasugrel a “priority” review lasting six months….